

**JOHNSON & JOHNSON**  
**SELECTED PHARMACEUTICALS IN LATE STAGE U.S. and E.U. DEVELOPMENT OR REGISTRATION**  
**As of October 13, 2009\***

<b>Therapeutic Area</b>	<b>Product Name</b>	<b>Indication Sought</b>	<b>U.S. Development Stage</b>	<b>E.U. Development Stage</b>	
<b>Central Nervous System</b>	INVEGA (paliperidone ER OROS)	Bipolar mania/ recurrence prevention Schizoaffective disorder	Phase III Approved 7/09	File withdrawn 12/08 Filed 8/09	
	INVEGA SUSTENNA (paliperidone palmitate IM long acting injectable )	Schizophrenia (1)	Approved 7/09	Phase III	
	RISPERDAL CONSTA (risperidone)	Bipolar maintenance - long acting injectable (2), Deltoid injection (2) (5)	Approved 5/09 Approved 10/08	Filed 12/08 Approved 7/09	
	bapineuzumab	Alzheimer's disease (7)	Phase III		
	COMFYDE (carisbamate)	Epilepsy (6)	FDA Complete Response letter 8/09	Filed 8/09	
	CONCERTA (OROS methylphenidate)	Adult attention deficit hyperactivity disorder	Approved 6/08	Phase III	
<b>Gastrointestinal</b>	REMICADE (infliximab)	Pediatric Ulcerative Colitis	Phase III		
<b>Immunology</b>	STELARA (ustekinumab)	Psoriasis (SC)	Approved 9/09	Approved 1/09	
	SIMPONI (golimumab)	Rheumatoid Arthritis (SC) Ankylosing Spondylitis (SC) Psoriatic Arthritis (SC) Rheumatoid Arthritis (IV) Structural Damage (RA, PsA) Ulcerative Colitis	Approved 4/09 Approved 4/09 Approved 4/09 Phase III Phase III Phase III	Approved 10/09 (3) Approved 10/09 (3) Approved 10/09 (3) Phase III (3) Phase III (3) Phase III (3)	
	PROCRIT (epoetin alfa)	Chronic Renal Function - extended dosing Myelodysplastic Syndrome	Phase III Phase III		
	<b>Infectious Disease</b>	ZEFTERA/ZEVTERA (ceftobiprole )	Complicated Skin and Skin Structure Infections (6) Nosocomial Pneumonia (6) Hospitalized community acquired pneumonia (CAP) (6)	FDA Complete Response letter 11/08 Phase III Phase III	CHMP Decision on hold 2/09 Phase III Phase III
		DORIBAX (doripenem)	Nosocomial Pneumonia (6)	FDA Complete Response letter 8/08	Approved 7/08
	<b>Oncology</b>	DOXIL (doxorubicin HCl liposome injection)	Breast Cancer (metastatic)	FDA Complete Response letter 9/09	
VELCADE (bortezomib)		Non-Hodgkin's Lymphoma (6) Mantle Cell Lymphoma 1st line (6) Subcutaneous formulation		Phase III Phase III Phase III	
YONDELIS (trabectedin)		Relapsed Ovarian Cancer (6)	FDA Complete Response letter 9/09		
abiraterone		Prostate cancer (chemo-refractory and chemo naïve)	Phase III	Phase III	
DACOGEN (decitabine) for Injection		Myelodysplastic Syndromes (MDS) (6) Acute Myeloid Leukemia (6)		Phase III Phase III	
<b>Anti-Viral</b>	telaprevir	Chronic hepatitis C virus (HCV) infection		Phase III (6)	
	TMC278	NNRTI HIV/AIDS treatment-naïve patients	Phase III	Phase III	
<b>Pain Management</b>	NUCYNTA ER (tapentadol )	Moderate to severe chronic pain (Extended Release formulation) (6)	Phase III		
<b>Cardiovascular/Metabolism</b>	rivaroxaban	VTE Prophylaxis (Prevention of venous thromboembolism in hip and knee replacement surgery) (6) Stroke prevention in atrial fibrillation (6) VTE treatment (6) Acute Coronary Syndrome (6) Medically III (6)	FDA Complete Response letter 5/09  Phase III Phase III Phase III Phase III		
	canagliflozin	Type 2 diabetes (6)	Phase III	Phase III	
<b>Sexual Health</b>	PRILIGY (dapoxetine)	Premature ejaculation (6)	FDA non-approvable letter 10/05	Approved 2/09 (4)	

\* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information

- (1) Collaboration with Elan Corporation, plc
- (2) Collaboration with Alkermes, Inc.. EU filings submitted as Type II Variations
- (3) Schering-Plough has EU marketing rights
- (4) Select EU countries
- (5) PK Trial - comparative single-dose pharmacokinetics of deltoid and gluteal injection
- (6) Comfyde™ licensed from SK-Bio Pharmaceuticals, Zeftera/Zevtera™ developed in collaboration with Basilea Pharmaceutica, Doribax™ developed in collaboration with Shionogi & Co., Velcade® developed in collaboration with Millennium Pharmaceuticals, The Takeda Oncology Company, Yondelis® developed in collaboration with PharmaMar, Dacogen® developed in collaboration with Eisai Corporation of North America, Nucynta™ co-developed with Grunenthal GMBH, rivaroxaban co-developed with Bayer HealthCare, Priligy® developed in collaboration with PPD-GenuPro, telaprevir developed in collaboration with Vertex Pharmaceuticals Incorporated, canagliflozin licensed from Mitsubishi Tanabe Pharma Corporation
- (7) Acquired from Elan Pharmaceuticals plc and being developed in collaboration with Wyeth